Clinical TrialsSearch results
Number of results: 605
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Investigation of the Effect of Combined Mouthwash with SP-T Medical Gargle and Scaling on Periodontal Disease
- Periodontal disease
- Sugaya Tsutomu
- 2023-09-15
Recruiting
- Dose Comparison Study of Intravenous ICG Dose in Lung Malignant Tumor Localization Method Using Fluorescence Spectroscopy Syste
- Primary lung cancer(or suspicious), or metastatic lung tumor (or suspicious)
- Kato Tatsuya
- 2023-09-11
Recruiting
- A study on Nano-Sized Electrostatic Atomized Water Particles environment.
- cold syndrome
- Konno Satoshi
- 2023-07-26
Recruiting
- Effect of tofogliflozin on pancreatic beta-cell function
- Type 2 diabetes
- Nakamura Akinobu
- 2023-05-09
Recruiting
- Exploratory research investigating the impact of the total neoaduvant therapy for locally advanced rectal cancer.
- Rectal cancer
- Taketomi Akinobu
- 2022-09-27
Recruiting
- Dabrafenib and Trametinib in pediatric patients with refractory advanced Solid Tumors with BRAF V600 mutations
- 12 months to 15 year- old patients with unresectable or refractory solid cancer with BRAF V600
- Kinoshita Ichiro
- 2022-09-01
Recruiting
- A Phase III Study of Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib and Dexamethasone in Participants with RRMM
- Relapsed/Refractory Multiple Myeloma
- Kakinuma Yuki
- 2022-02-01
Recruiting
- Phase II trial of docetaxel/pembrolizumab in head and neck squamous cell carcinoma
- head and neck squamous cell carcinoma
- Shimizu Yasushi
- 2022-02-01
Recruiting
- A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
- Lupus Nephritis
- Tanaka Yoshiya
- 2021-12-25
Recruiting
- Phase 3 Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)
- NSCLC Harboring HER2 Exon 19 or 20 Mutations
- Inoguchi Akihiro
- 2021-12-23